Clinical Trial NCI UPMC14M01
- A Randomized Phase II Study of Sequential Biotherapy with Aflibercept and High Dose IL-2 versus High Dose IL-2 alone in Patients with Inoperable Stage III or Stage IV Melanoma: Efficacy and Biomarker Study
- Principal Investigator
- Timothy Kuzel
- Status: Accepting New Patients
- Study Type: Therapeutic, Treatment
- Protocol No:.NCI UPMC14M01
- The purpose of this study is to see whether the combination of the two drugs aflibercept and interleukin-2 (IL-2) will help prevent the growth of your cancer. This study is being done to see if giving IL-2 and aflibercept together (in combination) is more effective in treating your cancer (metastatic melanoma) than IL-2 or aflibercept given by themselves. This study is also being done to look at the severity of the side effects caused by this combination treatment.
- IL-2 is approved by the Food and Drug Administration for the treatment of melanoma. Aflibercept (also called VEGF Trap) is an investigational or experimental anti-cancer drug. That means it has not been approved by the Food and Drug Administration for use in patients with melanoma. The development of new blood vessels is essential for tumors to grow and survive. Vascular endothelial growth factor (VEGF) is an important molecule which drives angiogenesis (the formation of new blood vessels). The experimental drug aflibercept inactivates VEGF from functioning and scientific experiments have shown that when VEGF is prevented from working, new blood vessels don’t form in tumors and these tumors do not grow. Aflibercept has been used to treat patients with various types of cancers. Some patients with melanoma, lung, ovarian, bladder or kidney cancer have responded well to VEGF Trap. In addition, there is scientific evidence that supports the combination of aflibercept with interleukin-2, so this drug will now be evaluated in combination with interleukin-2 in patients with melanoma.
Some of the eligibility criteria include:
- Participants in this study must have metastatic melanoma.
- Participants may have had up to two prior treatment regimens for their metastatic melanoma.
- Participants must be 16 or older.
- Description of Treatment
- Participants will be randomly assigned to either Arm A or Arm B. For participants in Arm A aflibercept will be administered intravenously (through a vein in the arm). It will be repeated every 2 weeks as long as the cancer has not progressed and the doctor determines it is safe to continue aflibercept. IL-2 therapy will also be given intravenously (into a vein). IL-2 will be given for a maximum of 6 cycles. For each cycle of IL-2, participants will be admitted to the hospital to receive IL-2 every 8 hours for 5 days (a maximum of 14 doses). For participants in Arm B IL-2 will be given according to the standard of care for the treatment of melanoma. IL-2 is given intravenously (into a vein). Participants will receive a maximum of 3 courses, or 6 cycles.
- Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
Find Related Clinical Trials
Browse by Disease Sites
Other Clinical Trials by Timothy Kuzel
- Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
- Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma
- A Randomized, Open-Label, Phase 3 Trial of brentuximab vedotin (SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
- A Phase Ib/II Trial of ALT-801 in Combination with Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
- A Phase 1 Open-label Study of Safety and Tolerability of MEDI4736 in Subjects with Metastatic or Unresectable Melanoma in Combination with Dabrafenib and Trametinib or with Trametinib Alone
- A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has Progressed after Prior VEGFR Tyrosine Kinase Inhibitor Therapy
- A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features
- A Phase II Trial of Dasatinib in Patients with Unresectable Locally Advanced or Stage IV Mucosal, Acral and Solar Melanomas
- Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
- A Randomized Phase II Study of Ipilimumab at 3 mg/kg or 10 mg/kg Alone or in Combination with High Dose Interferon-a in Advanced Melanoma
- A Randomized Phase II Trial of Ipilimumab with or without Bevacizumab in Patients with Unresectable Stage III or Stage IV Melanoma
- A Randomized Phase I Dose-Escalation Trial of Carfilzomib with and without Romidepsin in Cutaneous T-Cell Lymphoma
- Phase II Trial of Everolimus or Everolimus plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients with Advanced Urothelial Carcinoma (GU10-147)
- A Phase 1/2 study combining Ipilimumab with Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-Naïve Patients with Progressive Metastatic Castration-Resistant Prostate Cancer
last updated: 01-Feb-15 03:09 PM
Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.